News Releases

Webcast Image Webcast
Jaguar Health - Investor Conference Call
Aug 13, 2020 at 8:30 AM EDT
Date Title  
Toggle Summary Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the third-party, investigator-initiated Phase 2 HALT-D trial evaluating crofelemer for the prevention
Toggle Summary Jaguar Health Reports 2021 Third Quarter Financial Results
Mytesi ® prescription volume increased 7.6% in Q3 2021 over Q2 2021 Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million Company expects to complete transition to selling Mytesi through closed specialty pharmacy network by end of 2021 as part
Toggle Summary Jaguar Health's Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager
REMINDER: Jaguar to host investor webcast Wednesday, November 17th at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / November 16, 2021 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time
Click here to register for webcast Company plans to file Q3 2021 10-Q on November 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company's investor webcast to review third-quarter 2021 financials and provide business
Toggle Summary Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates
Click here to register for webcast Company plans to file Q3 2021 10-Q on November 15, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host a webcast on Monday, November 15, 2021 at 8:30 a.m.
Toggle Summary Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the appointment by Napo EU S.p.A., the company's Italian subsidiary, of Annabella Amatulli as chief regulatory officer. A recognized expert in global regulatory affairs, Ms.
Toggle Summary Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch
Canalevia ™ -CA1 is the first and only oral plant-based prescription drug candidate for CID in dogs Jaguar kicks off educational awareness contest in honor of International Jaguar Day; Click here to enter SAN FRANCISCO, CA / ACCESSWIRE / November 2, 2021 /   Jaguar Health, Inc.
Toggle Summary The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed
The combined entity is named Napo EU S.p.A. SAN FRANCISCO, CA / ACCESSWIRE / November 1, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the merger of its Italian subsidiary Napo EU S.p.A. and Dragon SPAC S.p.A. has closed. "We know shareholders and other stakeholders have been
Toggle Summary Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that, effective October 25, 2021 , the Company granted nonstatutory stock options for the purchase of up to 2,666 shares of the Company's common stock to New Employee
Toggle Summary Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing
Merger expected to be effective within a week The combined entity will be named Napo EU S.p.A. Merger effects the exclusive license agreement between Jaguar and Napo EU S.p.A. including up-front license fee due to Jaguar Napo EU S.p.A.'s initial focus is on the conditional marketing authorization
Toggle Summary Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.
Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger Results accepted for third-party, investigator-initiated Phase 2 HALT-D study evaluating crofelemer for prevention and prophylaxis of diarrhea in breast cancer
Toggle Summary Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award
Award celebrates Ms. Conte's 30-year, unrelenting commitment to supporting Indigenous communities in the Amazon and responsibly harvesting and commercializing the first-ever plant-based oral medicine approved under FDA Botanical Guidance SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2021 /  
Toggle Summary Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021
Leading oncologists discuss importance of supportive care for cancer patients to address debilitating diarrhea resulting from cancer therapy Virtual event 1:00 PM to 2:10 PM Eastern Registration open now for financial and business community; Click here to register SAN FRANCISCO, CA / ACCESSWIRE /
Toggle Summary Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar planning for launch of Canalevia ™ for CID in dogs this December Canalevia is the first and only oral plant-based prescription drug candidate for CID in dogs SAN FRANCISCO, CA / ACCESSWIRE / September 23, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that it was informed on
Toggle Summary REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time
Click here to register for webcast Jaguar kicks off educational awareness contest in honor of Indigenous Peoples' Day; Click here to enter SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that company management will host a webcast on Monday,
Toggle Summary Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency
The conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo Pharmaceuticals Jaguar to host investor webcast Monday, September 20th at 8:30 a.m.
Toggle Summary Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
Participating investors include Jaguar CEO and CFO, Dragon SPAC S.p.A. sponsor Josh Mailman , and plant-based pharmaceutical manufacturing pioneer Indena S.p.A . Company to host investor webcast Monday, September 20th at 8:30 a.m. Eastern Click here to register for webcast SAN FRANCISCO, CA /
Toggle Summary Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director
Appointments represent Jaguar's focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization of crofelemer prescription product for chemotherapy-induced diarrhea in dogs Company to host
Toggle Summary Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split
Reverse split approved by majority of common stock shareholders at December 2020 special meeting of stockholders Shares of Jaguar common stock to begin trading on split-adjusted basis on September 8, 2021 SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders
Proposals 1, 2, 4, 5 & 6 approved SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's May 13, 2021 Annual Meeting of Stockholders, which was adjourned until September 3, 2021 .
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting
Exploratory study evaluating effects of crofelemer on gut microbiome SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 /   Napo Pharmaceuticals , the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with an exploratory clinical study on the
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe
Per the terms of the agreement, Napo Pharmaceuticals will receive an upfront payment of $10 million payable in two installments following the anticipated merger of Napo EU and Dragon SPAC S.p.A. and is eligible to receive additional payments related to milestones, royalties, and product transfers
Toggle Summary Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea
In support of planned Investigational New Drug application for lechlemer, Napo Pharmaceuticals , Jaguar's wholly owned subsidiary, received comprehensive animal toxicity preclinical services supported by the National Institute of Allergy and Infectious Diseases for four studies SAN FRANCISCO, CA /
Toggle Summary Jaguar Health, Inc. Reports 2021 Second Quarter Financial Results
Second quarter 2021 Mytesi ® net and gross sales were approximately $0.4 million and approximately $4.9 million Company transitioning to primarily selling Mytesi directly through selected specialty pharmacies as part of Company's market access strategy Company to host investor webcast Friday,
Toggle Summary Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time
Registration link for webcast appears below Company plans to file Q2 2021 10-Q on August 13, 2021 SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company investor webcast scheduled for Friday, August 13,
Toggle Summary Jaguar Health to Host Investor Webcast Friday, August 13th at 8:30 AM Eastern Time Regarding Q2 2021 Financials & Business Updates
Registration link for webcast appears below Company plans to file Q2 2021 10-Q on August 13, 2021 Jaguar kicks off educational awareness contest in honor of African Traditional Medicine Day SAN FRANCISCO, CA / ACCESWIRE / August 10, 2021 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote
Based on a preliminary review of votes cast, over 75% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene September 3, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum SAN FRANCISCO, CA / ACCESSWIRE / August 6, 2021 /   Jaguar Health, Inc.
Toggle Summary REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Interview with Lisa Conte to Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 28, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that an Innovators with Jane King interview of Lisa Conte , the company's founder, president, and CEO, and member of the board of directors of Napo
Toggle Summary Jaguar Health Announces that Innovators with Jane King Interview with Lisa Conte will Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that an Innovators with Jane King interview of Lisa Conte , the company's founder, president, and CEO, will be aired during an investor webcast on
Toggle Summary Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') announced today that effective July 15, 2021 , the Company granted nonstatutory stock options for the purchase of up to 8,000 shares of the Company's common stock to New Employee 1 and
Toggle Summary Napo EU S.p.A., Jaguar Health's Italian Subsidiary, and Dragon SPAC S.p.A. Announce Close of 8,830,000 Euro Dragon SPAC Financing
Napo EU, the identified target of Dragon SPAC, seeks to develop plant-based crofelemer to potentially treat orphan disease - short bowel syndrome (crofelemer has received orphan-drug designation from the US FDA for SBS) Merger of Napo EU & Dragon SPAC expected to be effective within approximately
Toggle Summary Jaguar Health Announces Completion of Investigator-Initiated Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients
Abstract of study results submitted by the third-party investigators to December 2021 San Antonio Breast Cancer Symposium SAN FRANCISCO, CA / ACCESSWIRE / July 14, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the third-party, investigator-initiated Phase 2 HALT-D study evaluating
Toggle Summary Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, August 6, 2021 and Encourages All Shareholders to Vote
Based on a preliminary review of votes cast, over 74% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene August 6, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum SAN FRANCISCO, CA / ACCESSWIRE / July 9, 2021 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health Set to Join Russell Microcap Index
Jaguar kicks off educational awareness contest about medicinal plants SAN FRANCISCO, CA / ACCESSWIRE / June 23, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Jaguar is set to join the Russell Microcap ® Index at the conclusion of the 2021 Russell
Toggle Summary Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, July 9, 2021 and Encourages All Shareholders to Vote
Based on a preliminary review of votes cast, over 76% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene July 9, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum SAN FRANSICO, CA / ACCESSWIRE / June 11, 2021 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / June 4, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective May 27, 2021 , the Company granted nonstatutory stock options for the purchase of up to 225,000 shares of the Company's common stock to a new employee, as
Toggle Summary REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM Eastern
Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / June 2, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today that an Innovators with Jane King webcast interview with Jaguar CEO Lisa Conte & Dragon SPAC S.p.A.
Toggle Summary Napo EU S.p.A., Jaguar Health’s Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU
Jaguar & Dragon SPAC announce initial funding of $10.8 million into Dragon SPAC Napo EU to focus initially on conditional approval for an important orphan indication, short bowel syndrome (SBS), a condition leading to intestinal failure Innovators with Jane King webcast interview with Jaguar CEO
Toggle Summary Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC
Napo EU S.p.A., named target of Dragon SPAC, provides update on plan to pursue conditional marketing authorization for crofelemer in EU Equita Group S.p.A., a leading Italian based investment bank, advising Dragon SPAC; Cantor Fitzgerald & Co. advising Jaguar on non-deal related activities SAN
Toggle Summary Napo Pharmaceuticals, Jaguar Health’s Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical Officer
SAN FRANCISCO, CA / ACCESSWIRE / May 26, 2021 / Napo Pharmaceuticals Inc. , the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), announced today the appointment of Darlene Horton , M.D., a biopharmaceutical veteran and leading clinical development expert, to
Toggle Summary Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting
SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea ("CRD") by Napo Pharmaceuticals, Inc.
Toggle Summary Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community
Newly created Jaguar Health Community Instagram page introduces jaguar-themed contest SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company recently launched a new social media channel for stakeholders and
Toggle Summary Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs
Canalevia would be first and only FDA-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapy Canalevia will be available by fourth quarter 2021, if conditionally approved SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health, Inc. Reports 2021 First Quarter Financial Results
First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million , increases of 250% and 43%, respectively Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern regarding first quarter 2021 financials & business updates SAN
Toggle Summary Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective May 12, 2021 , the Company granted nonstatutory stock options for the purchase of up to 4,000 shares of the Company's common stock to New Employee 1,
Toggle Summary Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote
Based on a preliminary review of votes cast, over 80% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene June 11, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum Reminder: Jaguar to host investor webcast Monday, May 17th at 8:30 AM Eastern Time
Toggle Summary Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates
Webcast registration link appears below Company plans to file Q1 2021 10-Q on May 17, 2021   SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a webcast on Monday, May 17, 2021 at 8:30
Toggle Summary Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan
Company terminates at-the-market (ATM) financing program SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement (the "Transaction") with North American institutional
Toggle Summary Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract Regarding Patient Outcomes Associated with Cancer Therapy-Related Diarrhea Accepted for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting
SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's
Toggle Summary REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar’s New Italian Subsidiary
Registration link for webcast interview appears below SAN FRANCISCO, CA / ACCESSWIRE / April 21, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today about the Innovators with Jane King interview of Lisa Conte , the Company's founder, president, and CEO,
Toggle Summary Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary
Registration link for webcast interview appears below Company premiers Napo EU's new logo and branding, now live on Napoeu.com website SAN FRANCISCO, CA / ACCESSWIRE /   April 19, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that an Innovators with Jane
Toggle Summary Jaguar Health Announces Upsizing of At-the-Market (ATM) Financing Program by $15.3 Million with Ladenburg Thalmann & Co. Inc. for Potential Future Financing Needs
Merger of Napo EU and Dragon SPAC targeted for mid-2021 Jaguar kicks off educational awareness contest in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV SAN FRANCISCO, CA / ACCESSWIRE / April 15, 2021 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health and Napo Pharmaceuticals Announce Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Annual Meeting
SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's collaborators has been accepted for
Toggle Summary Jaguar Health Announces Amendment to March 2020 Equity Purchase Agreement with Oasis Capital, LLC
Stock purchase price under the agreement increases to $3.00 per share SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar has entered into an amendment (the "Amendment") to the March 24, 2020 equity purchase agreement (the "Equity
Toggle Summary Jaguar Health Promotes Carol Lizak to Chief Financial Officer
SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has promoted Carol Lizak , an accomplished financial executive, to the expanded role of chief financial officer.
Toggle Summary Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective March 26, 2021 , the Company granted nonstatutory stock options for the purchase of up to 2,000 shares of the Company's common stock to new employee 1,
Toggle Summary Jaguar Health Reports 2020 Financial Results and Business Updates
Mytesi ® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2020 .
Toggle Summary Jaguar Health Announces Selection of Investment Bank and Nominated Advisor for Proposed Merger of the Dragon SPAC and Napo EU, Jaguar's Italian Subsidiary
Update regarding March 15, 2021 meeting with European regulatory authority regarding potential Covid-related indication for crofelemer SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company supports the
Toggle Summary Jaguar Health Announces Winner of International Day of Forests Contest
New educational contest to begin in April in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV SAN FRANCISCO, CA / ACCESSWIRE / March 22, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Maribel
Toggle Summary Jaguar Health Announces Incorporation of Napo EU Subsidiary in Italy
Napo EU will serve as the foundation of the Company's efforts to address the growing burden - particularly in Europe - of the inflammatory diarrhea associated with long-hauler syndrome in the post COVID-19 patient population In honor of International Day of Forests, Company is conducting a survey
Toggle Summary Jaguar Health Signs Definitive Agreement for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream
No royalty payments due for 36 months Company has started to identify key opinion leader physicians in the US as well as Europe focused on addressing the symptoms - including gastrointestinal distress - that afflict a significant proportion of COVID-19 survivors for an extended period after
Toggle Summary Jaguar Health Enters Binding Term Sheet for $5 Million Non-dilutive Financing Transaction Involving Sale of Royalty Rights Related to Future Potential Crofelemer (Mytesi) COVID-related Indication Revenue Stream
No royalty payments due for 36 months Planned COVID-related indication in long-hauler patients is the lead focus for crofelemer at Napo EU, the exclusive target of the planned Dragon SPAC, which is pursuing listing on AIM Italia Company expects to provide additional updates regarding Napo EU next
Toggle Summary Jaguar Health Launches Website for Napo EU
Site contains links to information about post-COVID-19 ‘long-hauler' syndrome An article published yesterday in the San Francisco Chronicle references diarrhea as long-hauler symptom and the theory that the type of inflammation associated with HIV may also be present in long-hauler patients Napo EU
Toggle Summary Jaguar Health Announces Commitment to Move Forward with Exclusive Relationship with the Planned Dragon SPAC, which is Pursuing Listing on AIM Italia and Plans to Target Napo EU
Napo EU continues to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in Europe SAN FRANSISCO, CA / ACCESSWIRE / February 19, 2021 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health Signs Memorandum of Understanding with the Lead Sponsor of the Planned Dragon SPAC Pursuing Listing on AIM Italia, Providing the Dragon SPAC with Exclusivity for a Proposed Business Combination with Napo EU
Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in Europe SAN FRANCISCO, CA / ACCESSWIRE / February 18, 2021 / Jaguar Health, Inc.
Toggle Summary Noted Natural Products Industry Veteran Dr. Nigel Gericke Joins Scientific Strategy Team for Jaguar Health’s Recently Launched Mental Health Entheogen Therapeutics Initiative
Team of advisors guides strategic research to discover and develop potential novel, natural psychoactive prescription medicines derived from Jaguar's library of 2,300 plants SAN FRANCISCO, CA / ACCESSWIRE / February 9, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that noted natural
Toggle Summary Jaguar Health's Chief of Sustainable Supply, Dr. Steven King, an Ethnobotanist, to Discuss Crofelemer Development on February 4th at 2 PM Eastern as Part of the American Botanical Council's Sustainable Herbs Program Webinar Series
Webinar Title: The Development of Crofelemer: Connecting Ethnobotany, Conservation, Biocultural Diversity, Indigenous Knowledge and Global Public Health Webinar registration link appears below Over the last 30 years, the Jaguar team and partner organizations have substantially invested in
Toggle Summary REMINDER: Jaguar Health and Sponsor of Proposed Post Pandemic Recovery Equity SPAC to Host Webcast Wednesday, January 27th at 8:30 AM Eastern Time to Provide Updates Regarding the Potential Merger of Napo EU, the Company’s Anticipated Subsidiary in Italy
Webcast registration link appears below Andreea Porcelli , CEO of Swiss Growth Forum , will be a co-presenter on the webcast in her separate capacity as a sponsor of the proposed SPAC Andreea Porcelli and Jaguar CEO Lisa Conte interviewed again on Innovators with Jane King SAN FRANCISCO, CA /
Toggle Summary Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / January 22, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective December 9, 2020 , the Company granted nonstatutory stock options for the purchase of up to 1,500 shares of the Company's common stock to one new
Toggle Summary Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
JAGX's securities continue to be listed on Nasdaq Stock Exchange SAN FRANCISCO, CA / ACCESSWIRE / January 22, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on January 21, 2021 the Company received formal notice that Jaguar has regained compliance with
Toggle Summary Jaguar Health and Sponsor of Proposed Post Pandemic Recovery Equity SPAC to Host Webcast Wednesday, January 27th at 8:30 AM Eastern Time to Provide Updates Regarding the Potential Merger of Napo EU, the Company’s Anticipated Subsidiary in Italy
Webcast registration link appears below Andreea Porcelli , CEO of Swiss Growth Forum , will be a co-presenter on the webcast in her separate capacity as a sponsor of the proposed SPAC   SAN FRANCISCO, CA / ACCESSWIRE / January 21, 2021 / Jaguar Health, Inc.
Toggle Summary Jaguar Health Announces Closing of $6.0 Million Issuance and Sale of Designation-backed Note Related to Possible Tropical Disease Priority Review Voucher
This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients and severe acute watery diarrhea SAN FRANCISCO, CA / ACCESSWIRE / January 20, 2021 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health Provides Replay Link & High-level Overview of January 14th Investor Webcast
SAN FRANCISCO, CA / ACCESSWIRE / January 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided the replay link for the Company's January 14, 2021 investor webcast and a recap of the key points from the presentation. To access the audio recording and slides from the
Toggle Summary Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher
This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time .
Toggle Summary Jaguar Health Announces $15 Million Registered Direct Offering Priced Above-the-Market Under Nasdaq Rules
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement with two institutional investors including a high-net-worth family office for the purchase and sale of 4,437,870
Toggle Summary Jaguar Health to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual Conference
REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time . Webcast registration link appears below Jaguar CEO Lisa Conte interviewed on Innovators with Jane King SAN FRANCISCO, CA / ACCESSWIRE / January 12, 2021 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ COVID-19 Recovery Patients in Europe
New COVID-19 strain estimated to have tripled number of infections in England during November 2020 lockdown Investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time . Webcast registration link appears below SAN FRANCISCO, CA / ACCESSWIRE / January 11, 2021 /   Jaguar Health,
Toggle Summary Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
Lechlemer development focused on possible tropical disease priority review voucher SAN FRANCISCO ,   CA / ACCESSWIRE / January 6, 2021 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the 28-day preclinical toxicology and safety study in dogs began today,
Toggle Summary Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream
No royalty payments due for 18-24 months Proceeds will be allocated to support regulatory activities associated with the Company's development pipeline, including funding the recently initiated pivotal clinical trial for crofelemer (Mytesi ® ) for cancer therapy-related diarrhea (CTD), for which
Toggle Summary Jaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor Webinar
All proposals approved Company not implementing a reverse split at this time Swiss Growth Forum hosting investor webinar Wednesday, December 23rd at 10:30 AM Eastern regarding appearance of new coronavirus strain underscoring urgency to seek European conditional approval for crofelemer for
Toggle Summary REMINDER: Jaguar Health to Host Investor Call Thursday, December 17, 2020 to Allow Management to Review Developments Since the Definitive Proxy Statement for the Company’s December 9, 2020 Special Meeting of Stockholders Was Filed
European road show completed for European Post Pandemic Recovery Equity special purpose acquisition company (SPAC) regarding potential merger with Napo EU, a subsidiary the Company plans to establish in Europe focusing on development of crofelemer for ‘long-hauler' post COVID-19 recovery patient
Toggle Summary Jaguar Health Announces Adjournment of Its Special Meeting of Stockholders Until Tuesday, December 22, 2020
Jaguar to Host Investor Call Thursday, December 17th at 8:30 a.m. Eastern to Allow Management to Review Developments that Have Taken Place Since the Definitive Proxy Statement was Filed As previously announced, Nasdaq's Listing and Hearing Review Council Stayed the Panel Determination Requiring
Toggle Summary Nasdaq's Listing and Hearing Review Council Stays Panel Determination Requiring Jaguar Health's Compliance with the Bid Price Requirement by December 23, 2020
The Nasdaq Listing Council , on its own motion, will consider if the Company should have been granted a longer period within which to evidence compliance with the $1.00 per share minimum bid price requirement SAN FRANCISCO, CA / ACCESSWIRE / December 7, 2020 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Fifth Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020
The Sixth Tranche Accounts Receivable has a gross value of $3,810,587.04 , representing customer billings over a 51-day period SAN FRANCISCO, CA / ACCESSWIRE / December 4, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals,
Toggle Summary Jaguar Health Announces Plan to Develop and Commercialize Crofelemer, the Company's Novel Proprietary Drug, for the Indication of Inflammatory Diarrhea, Initially in 'Long-Hauler' COVID-19 Recovery Patients
A significant percentage of COVID-19 recovery patients suffer from long-term diarrhea or other gastrointestinal disfunctions Non-binding terms to fund activities in Europe SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and the
Toggle Summary Jaguar Health Announces Release of Podcast Interview with The Wall Street Resource
SAN FRANCISCO, CA / ACCESSWIRE / November 24, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI
Toggle Summary Jaguar Health, Inc. Reports 2020 Third Quarter Financial Results
Third quarter 2020 Mytesi net sales and gross sales were approximately $2.8 million and approximately $6.3 million , respectively Company to host investor call Monday, November 16th at 8:30 a.m. Eastern regarding third quarter 2020 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE /
Toggle Summary Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates
Company Plans to File Q3 2020 10-Q on November 16, 2020 SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Monday, November 16, 2020 at 8:30 a.m.
Toggle Summary Jaguar Health Receives Positive Nasdaq Listing Determination
SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on October 28, 2020 the Company received formal notice that the Nasdaq Hearings Panel (the "Panel") granted Jaguar an extension through December 23, 2020 to
Toggle Summary Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer"
Leading Oncologists, Supportive Care Experts, and Patient Advocates Discuss Importance of Supportive Care for Cancer Patients and Address Debilitating Diarrhea Resulting from Cancer Therapy Virtual Event and Q&A 3:00 PM to 4:30 PM EDT on October 20 Registration Open for Financial and Business
Toggle Summary Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / October 16, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective October 13, 2020 , the Company has granted nonstatutory stock options for the purchase of up to 45,000 shares of the Company's common stock to one new
Toggle Summary Napo Pharmaceuticals, a Subsidiary of Jaguar Health, Launches Web-based NapoCares Platform to Enhance Patient Access to Mytesi
iAssist, a web-based component of the NapoCares ™ patient support program, automates and streamlines the patient prescription process SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that its wholly owned subsidiary, Napo Pharmaceuticals, Inc.
Toggle Summary Jaguar Health and Its Subsidiary Bolster Management Team with Appointment of Melissa Yeager, J.D. as Senior Vice President, Regulatory Affairs & Quality Assurance
Company Strengthens its Regulatory and Quality Capabilities to Support Mytesi ® Commercial Markets as Well as Ongoing Clinical Studies Including the Pivotal Phase 3 Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy SAN FRANCISCO, CA / ACCESSWIRE / October 14,
Toggle Summary Jaguar Health Provides Updates Regarding Company Capitalization Strategy
Jaguar Has Closed on the First $6 Million Tranche of the Previously Announced Non-Dilutive Royalty Financing Transaction - Which Now Has the Potential to Total $17 Million   Jaguar and its Subsidiary, Napo Pharmaceuticals , Enter into Fourth Amendment to the Accounts Receivable Purchase Agreement
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Crofelemer (Mytesi) for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy
A Significant Proportion of Patients Receiving Targeted Cancer Therapy Experience Diarrhea Initial Tranche of Non-dilutive Financing Transaction Increased from $5 Million to $6 Million by Mutual Consent with Lender, Providing Additional Q4 2020 Funding for Pivotal Phase 3 Clinical Trial and a Total
Toggle Summary Jaguar Health Meets Financial Condition for Sale of Royalty Rights for Mytesi (Crofelemer) Indications
Financial Condition for Initial $5 Million Tranche of Potential $16 Million   Non-dilutive Financing Transaction Achieved through the Establishment of an At-the-Market Program Yesterday for Potential Future Financing Needs, if Any, with Ladenburg Thalmann Aggregate Royalty Proceeds of Potential $16
Toggle Summary Jaguar Health's Mental Health Entheogen Therapeutics Initiative Targets Plant-based Candidate Compound for Possible Schizophrenia and Psychoses Indications
Neuropharmacological profile shows alstonine demonstrates antipsychotic activity and has a mechanism of action distinct from existing therapies SAN FRANCISCO, CA / ACCESSWIRE / October 2, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's recently launched mental health
Toggle Summary Jaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 Million
Proceeds Will Be Allocated to Support Regulatory Activities Associated with the Company's Development Pipeline, Including Funding the Pivotal Clinical Trial for Mytesi for Cancer Therapy-Related Diarrhea (CTD) Pivotal CTD Trial Expected to Initiate in Q4 2020 SAN FRANCISCO, CA / ACCESSWIRE /
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Sponsoring 2020 National Trans Visibility March
Napo to host virtual workshop September 30 th about the GI consequences of HIV SAN FRANCISCO, CA / ACCESSWIRE / September 28, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's wholly owned subsidiary, Napo Pharmaceuticals, Inc.
Toggle Summary Jaguar Health to Host Exclusive Virtual Educational Event “Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer”
Leading Oncologists, Supportive Care Experts, and Patient Advocates Discuss Importance of Supportive Care for Cancer Patients and Address Debilitating Diarrhea Resulting from Cancer Therapy Virtual Event and Q&A 3:00 PM to 4:30 PM EDT on October 20 Registration Open Now for Financial and Business
Toggle Summary Jaguar Health Establishes World-Class Scientific Strategy Team to Support Newly Launched Mental Health Entheogen Therapeutics Initiative
Team of advisors will guide strategic research to discover and develop potential novel, natural psychoactive prescription medicines derived from Jaguar's library of 2,300 plants SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2020 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health to Present at Virtual H.C. Wainwright 22nd Annual Global Investment Conference September 16
SAN FRANCISCO, CA / ACCESSWIRE / September 11, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today announced that Lisa Conte , Jaguar's founder, president and CEO, will present at the virtual 2020 H.C. Wainwright 22 nd Annual Global Investment Conference on Wednesday, September 16, 2020 , at
Toggle Summary Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020
The Fourth Tranche Accounts Receivable has a gross value of $2,329,662.72 , representing customer billings over a 24-day period SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo
Toggle Summary Jaguar Launches Mental Health Entheogen Therapeutics Initiative to Develop Novel, Natural Prescription Medicines Derived from Psychoactive Plants
Initiative includes leading ethnobotanists and will leverage Jaguar's plant-based medicines expertise and proprietary library of 2,300 medicinal plants Jaguar and its subsidiary Napo Pharmaceuticals uniquely suited to lead this effort based on successful development and commercialization of Napo's
Toggle Summary Jaguar Health Completes Transactions that Increase Stockholders' Equity Above $5,000,000
Amount Exceeds Minimum Stockholders' Equity Requirement for Initial Listing on The Nasdaq Capital Market SAN FRANCISCO, CA / ACCESSWIRE / September 2, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has completed transactions that it believes
Toggle Summary Jaguar Health Provides Updates on Investigator-Initiated Trials of Crofelemer (Mytesi)
Company shares updates on investigator-initiated trials of crofelemer (Mytesi ® ), a novel FDA-approved plant-based oral prescription medicine SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) today provided updates regarding ongoing investigator-initiated
Toggle Summary Jaguar Health Submits Final Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
Canalevia would be first and only FDA-approved plant-based medicine for the more than 50,000 dogs that suffer from diarrhea during chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / August 18, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) announced today that it has submitted to the U.S.
Toggle Summary Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into a Second Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020
SAN FRANCISCO, CA / ACCESSWIRE / August 14, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc. , (collectively, the "Company") have jointly entered into a second amendment to the accounts receivable purchase agreement
Toggle Summary Jaguar Health, Inc. Reports 2020 Second Quarter Financial Results
Q2 2020 Mytesi net sales and gross sales were approximately $3.2 million and approximately $6.3 million , respectively Reminder: Company to host investor call Thursday, August 13th at 8:30 a.m. Eastern regarding Q2 2020 financials & business updates Save the Date: Company to host virtual Diarrhea
Toggle Summary Jaguar Health to Host Investor Call August 13th at 8:30 a.m. Eastern Regarding Q2 2020 Financials and Business Updates
Company Plans to File Q2 2020 10-Q on August 13, 2020 Save the Date: Company to host virtual disease awareness event on October 20, 2020 focused on cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 11, 2020 /   Jaguar Health, Inc.
Toggle Summary Jaguar Health Announces Activation of Investigational New Drug (IND) for Crofelemer (Mytesi) for Prophylaxis and Symptomatic Relief of Cancer Therapy‑Related Diarrhea
A significant proportion of patients undergoing cancer therapy experience diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 6, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today the activation of the investigational new drug (IND) application filed by the
Toggle Summary Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / July 22, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective June 16, 2020 , the Company has granted nonstatutory stock options for the purchase of up to 30,000 shares of the Company's common stock to one new
Toggle Summary Jaguar Health Subsidiary Receiving Preclinical Services from the National Institute of Allergy and Infectious Diseases for New Preclinical Study Initiated July 21, 2020 for Lechlemer Plant-based Drug Candidate for Cholera
SAN FRANCISCO, CA / ACCESSWIRE / July 22, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the 28-day preclinical toxicology and safety study in rats began yesterday to support development of lechlemer, the second generation, plant-based anti-secretory
Toggle Summary Jaguar Health Reports Voting Results from July 21, 2020 Special Meeting of Stockholders
All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / July 21, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results from the Special Meeting of Stockholders of the Company (the "Special Meeting") that was held on July 21, 2020 .
Toggle Summary FDA Invites Jaguar Health to Expedite Submission of Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
Canalevia would be first and only FDA-approved plant-based medicine for the more than 50,000 dogs that suffer from diarrhea during chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / July 20, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that it has submitted to
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing of Investigational New Drug Application for Crofelemer (Mytesi) for Symptomatic Relief of Cancer Therapy‑Related Diarrhea
A significant proportion of patients undergoing cancer therapy experience diarrhea SAN FRANCISCO, CA / ACCESSWIRE / July 6, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's wholly owned subsidiary Napo Pharmaceuticals, Inc.
Toggle Summary Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
Canalevia would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea SAN FRANCISCO, CA / ACCESSWIRE / July 2, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that it has submitted to the U.S.
Toggle Summary Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter an Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020
Additional spring 2020 sales of Mytesi ® (beyond April 2020 sales) generate gross accounts receivable of $2,859,132 SAN FRANCISCO, CA / ACCESSWIRE / June 29, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc.
Toggle Summary Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / June 23, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective June 16, 2020 , the Company has granted nonstatutory stock options for the purchase of up to 3,318 shares of the Company's common stock to one new employee
Toggle Summary Preclinical Study Demonstrating Symptomatic Relief of Diarrhea in Dogs Receiving Neratinib in Combination with Crofelemer (Mytesi) Presented at American Association for Cancer Research Virtual Annual Meeting
Conducted by Jaguar Health subsidiary Napo Pharmaceuticals in collaboration with Puma Biotechnology, the study provides scientific rationale for the use of crofelemer in treating cancer patients receiving targeted therapy agents such as tyrosine kinase inhibitors SAN FRANCISCO, CA / ACCESSWIRE /
Toggle Summary On World Rainforest Day, Jaguar Health Reinforces Commitment to Amazon Rainforest and Sustainable Harvesting Programs for Plant-based Pharmaceuticals
Jaguar chief of sustainability and ethnobotanist Dr. Steven King speaks to Forest Trends about pharmacy of the forest, the power of Indigenous and local community knowledge, and the importance of corporate responsibility Over the last 30 years, the Jaguar team and partner organizations have
Toggle Summary Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / June 19, 2020 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Board of Directors of the Company (the "Board") adopted the Jaguar Health, Inc. New Employee Inducement Award Plan (the "Inducement Award Plan"), effective June
Toggle Summary Jaguar Health Submits Final Major Regulatory Filing for Approval of Canalevia (Crofelemer) to Treat Chemotherapy-induced Diarrhea in Dogs
Canalevia would be first and only FDA-approved plant-based medicine for 50,000-plus dogs that suffer from diarrhea during chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / May 28, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that it has submitted to the U.S.
Toggle Summary Jaguar Health Sustainability Leader Interviewed on Foodie Pharmacology Podcast
Dr. Steven King discusses tree-to-bottle development of Jaguar's Mytesi, the only oral plant-based medicine approved by FDA under botanical guidance SAN FRANCISCO, CA / ACCESSWIRE / May 26, 2020 / Jaguar Health, Inc. 's (NASDAQ:JAGX) head of sustainability Steven King , Ph.D., was interviewed on
Toggle Summary Jaguar Health Announces Exercise of Warrants for $4.45 Million Gross Proceeds
SAN FRANCISCO, CA / ACCESSWIRE / May 22, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that it has entered into agreements with several institutional and accredited investors wherein the investors agreed to exercise certain outstanding warrants to purchase an
Toggle Summary Jaguar Health Pursuing Contracting Opportunities with Insurers to Improve Patient Access for Company's Non-opioid Plant-Based Mytesi Drug Product
A component of Napo's new market access program intended to help remove access barriers for people living with HIV to start and stay on Mytesi ® SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company's wholly owned subsidiary, Napo
Toggle Summary Jaguar Health Reports Voting Results from May 15, 2020 Annual Meeting of Stockholders
All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / May 15, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results from the Annual Meeting of Stockholders of the Company (the "Annual Meeting") that was held on May 15, 2020 .
Toggle Summary Jaguar Health, Inc. Reports 2020 First Quarter Financial Results
Reminder: Company to host investor call today at 8:30 a.m. Eastern SAN FRANCISCO, CA / ACCESSWIRE / May 15, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated first quarter 2020 financial results. "We remain fully committed to expanding access to Mytesi
Toggle Summary Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter Accounts Receivable Purchase Agreement with Oasis Capital, LLC
April 2020 sales of Mytesi ® generate gross accounts receivable of $2,753,639 SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc. , (collectively, the "Company") have jointly
Toggle Summary Jaguar Health to Host Investor Call May 15th at 8:30 a.m. Eastern Regarding Q1 2020 Financials & Business Updates
Company Plans to File Q1 2020 10-Q on May 14, 2020 SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Friday, May 15, 2020 at 8:30 a.m.
Toggle Summary Jaguar Health Clears Important Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Exercise-Induced Diarrhea (EID) in Dogs
Canalevia is the first and only oral plant-based prescription drug candidate for EID in dogs Diarrhea is a common problem among working dogs subjected to intense, long-duration off-leash exercise SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2020 / Jaguar Health, Inc.
Toggle Summary Jaguar Health Enters Deal with Atlas Sciences to Develop NP-500, a Jaguar Non-Core Plant-based Type II Diabetes Drug Candidate
Jaguar concurrently receives $1.5 million and exclusive 10-year license from purchaser to develop and commercialize NP-500 through sale of NP-500 technology and IP Deal brings in immediate non-dilutive capital to fund pipeline of plant-based prescription drug candidates of Jaguar's Napo
Toggle Summary Jaguar Health Reports 2019 Financial Results and Business Updates
Mytesi ® net sales and gross sales grew 38% and 44%, respectively, in 2019 compared to 2018 Reminder: Company to host investor call Monday, April 6 at 8:30 a.m. Eastern SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported
Toggle Summary Jaguar Health to Host Investor Call April 6th at 8:30 a.m. Eastern Regarding Q4 2019 Financials & Business Updates
Company Filed its Annual Report on April 3, 2020 on Form 10-K for the Fiscal Year Ended December 31, 2019 SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Monday,
Toggle Summary Napo Pharmaceuticals Expands Mytesi (Crofelemer) Patient Support Program
NapoCares ™ patient support program provides FDA-approved, plant-based non-opioid Mytesi ® to treat non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy Launch of expanded NapoCares program during COVID-19 pandemic should especially benefit Mytesi patients who may have lost
Toggle Summary Jaguar Health Clears Key Regulatory Hurdle on Path to Approval of Canalevia (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs
Canalevia would be first and only FDA-approved plant-based medicine for 50,000-plus dogs that suffer from diarrhea annually while undergoing chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / April 1, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that it has
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Alleen King-Carter March 13, 2020 at 3 p.m. Eastern
SAN FRANCISCO, CA / ACCESSWIRE / March 12, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), is hosting a Facebook Live conversation at 3 p.m.
Toggle Summary Jaguar Health Secures Non-dilutive Capital Through Sale of Royalty Rights Related to Future Mytesi Revenue Stream
Transaction Proceeds Will be Allocated to Support Advancement of Regulatory Activities Associated with Jaguar's Pipeline, Including the Company's Lead Product Candidate, Crofelemer, for Cancer Therapy-related Diarrhea SAN FRANCISCO, CA / ACCESSWIRE / March 5, 2020 / Jaguar Health, Inc.
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Wins 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award
SAN FRANCISCO, CA / ACCESSWIRE / February 20, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the nonprofit American Botanical Council (ABC) has given the 2019 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to the Company's
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Davina Otalor February 7, 2020 at 3 p.m. Eastern
SAN FRANCISCO, CA / ACCESSWIRE / February 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), is hosting a Facebook Live conversation at 3 p.m.
Toggle Summary Jaguar Health Announces that Published Study Indicates Crofelemer Could be a Treatment Option for Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2020 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), today announced that a study appearing in the December 2019 issue of Clinical and Translational Gastroenterology , a peer-reviewed journal published by the American College of
Toggle Summary Jaguar Health Announces Study to Evaluate the Safety and Effectiveness of Crofelemer for Treatment of Chronic Idiopathic Diarrhea in Non-HIV Patients
SAN FRANCISCO, CA / ACCESSWIRE / December 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that a clinical research study initiated and sponsored by The University of Texas Health Science Center at Houston (UTHealth) will be supported by Jaguar's wholly-owned
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals to Host HIV Activism Digital Summit December 13, 2019 at 3 p.m. Eastern
SAN FRANCISCO, CA / ACCESSWIRE / December 10, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), is hosting an HIV Activism Digital Summit on Friday, December 13, 2019 from 3 p.m.
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with Transgender Advocate Yonce Jones November 22, 2019 at 3 p.m. Eastern
SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), is hosting a Facebook Live conversation at 3 p.m.
Toggle Summary Article About Jaguar Health Published in Fall 2019 Issue of MicroCap Review Magazine
SAN FRANCISCO, CA / ACCESSWIRE / November 20, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that an article about the Company appears in the Fall 2019 issue of MicroCap Review , a digital and print magazine delivering information about companies in the
Toggle Summary Jaguar Health, Inc. Reports 2019 Third Quarter Financial Results
Reminder: Company to Host Investor Call Today at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2019 / Jaguar Health, Inc.
Toggle Summary Jaguar Health Announces that Interim Analysis Requirement Met in Phase 2 HALT-D Study Evaluating Mytesi (Crofelemer) for Prevention and Prophylaxis of Diarrhea in Breast Cancer Patients
SAN FRANCISCO, CA / ACCESSWIRE / November 14, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that Georgetown University 's Data Safety Monitoring Committee ("DSMC") has reviewed the interim analysis for futility for the third-party, investigator-initiated
Toggle Summary Jaguar Health Appoints Ian Wendt Vice President, Commercial Strategy
Reminder: Company to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates SAN FRANCISCO, CA / ACCESSWIRE / November 13, 2019 / Jaguar Health, Inc.
Toggle Summary Jaguar Health to Host Investor Call Nov. 14th at 9 a.m. Eastern Regarding Interim Analysis of HALT-D Study of Mytesi (Crofelemer) for Prevention of Diarrhea in Breast Cancer Patients, Q3 Financials & Business Updates
Company Plans to File Q3 2019 10-Q on November 14, 2019 SAN FRANCISCO, CA / ACCESSWIRE / November 12, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Thursday, November 14th, 2019 at 9 a.m.
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Enters ex-U.S. Distribution Agreement for Mytesi (Crofelemer) with TannerGAP, Inc.
SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), has entered into a two-year distribution agreement ("the Agreement") with TannerGAP,
Toggle Summary Jaguar Health Announces Completion of Preclinical Studies of Lechlemer, the Company's Human Drug Product Candidate for Cholera and Acute Infectious Diarrhea
Napo Pharmaceuticals , Jaguar's Subsidiary, Received Preclinical Services from the National Institute of Allergy and Infectious Diseases for the Studies SAN FRANCISCO, CA / ACCESSWIRE / October 23, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today the completion
Toggle Summary Jaguar Health's Study Shows Mytesi (Crofelemer) May Support Treatment of Diarrhea in Cancer Patients Receiving Targeted Therapy While Also Enabling Maintenance and Tolerability of a Higher Dose of the Selected TKI
SAN FRANCISCO, CA / ACCESSWIRE / October 22, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced additional findings today from the recently completed preclinical study evaluating the effects of Mytesi ® (crofelemer) on diarrhea induced by a specific tyrosine kinase
Toggle Summary Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in China
Jaguar Health Receives $1.75 Million in Proceeds from Warrant Exercise at an Exercise Price of $1.40 SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2019 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company has engaged Angel Pond Capital LLC ("Angel
Toggle Summary Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer
SAN FRANCISCO, CA / ACCESSWIRE / October 4, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that a License Termination and Settlement agreement ("LTSA") related to SP-303, a component of Mytesi ® (crofelemer), has been entered between Michael Tempesta , Ph.D.
Toggle Summary Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs
Reminder: Company to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi ® (Crofelemer) for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea in Humans SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2019 / Jaguar Health, Inc.
Toggle Summary Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application
SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2019 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), has received a Notice of Allowance from the Canadian
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern
SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2019 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. ("Napo"), is hosting a Facebook Live conversation at 3 p.m.
Toggle Summary Jaguar Health to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Thursday, October 3rd, 2019 at 8 a.m. Eastern Time to provide updates regarding development of Mytesi ®
Toggle Summary Jaguar Health Comments on FDA's Decision to Set Packaging Limits for Anti-Diarrhea Medicine Loperamide (Imodium) to Encourage Safe Use
Mytesi ® Novel Anti-Diarrheal Mechanism of Action Distinguished as Non-Opioid SAN FRANCISCO, CA / ACCESSWIRE / September 23, 2019 /   Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued the following comments today regarding the September 20, 2019 announcement by the U.S.
Toggle Summary Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York
SAN FRANCISCO, CA / ACCESSWIRE / September 19, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Lisa Conte , Jaguar's founder, president and CEO, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019 , at 8:30 a.m.
Toggle Summary Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer
Company's Legacy Animal Health Business Supports Focus on Human Health Benefits SAN FRANCISCO, CA / ACCESSWIRE / September 18, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued the following updates today regarding the Company's September 11, 2019
Toggle Summary Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico
Puerto Rico Had the 7th Highest Cumulative Rate of HIV Infection in the Nation in 2016 SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the “Company”) announced today that the Drug and Pharmacy Division of the Government of Puerto Rico Health
Toggle Summary Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel
SAN FRANCISCO, CA / ACCESSWIRE / September 9, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) announced today that the Company has promoted Jonathan Wolin , an accomplished healthcare and biotech executive, to the expanded role of chief of staff, chief compliance officer and
Toggle Summary Jaguar Health Issues Regulatory Update Regarding Potential Indication for Crofelemer in Dogs
Company’s Legacy Animal Health Business Supports Focus on Human Health Benefits SAN FRANCISCO, CA / ACCESSWIRE / August 26, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) announced today that the Company is scheduled to meet with the U.S.
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Kamaria Laffrey August 23, 2019 at 3 p.m. Eastern
SAN FRANCISCO, CA / ACCESSWIRE / August 22, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), today announced that the Company’s wholly-owned, human-health focused subsidiary, Napo Pharmaceuticals, Inc. (“Napo”), is hosting a Facebook Live conversation at 3 p.m.
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Appoints Brian Sutton National Business Director
SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company’s wholly-owned,
Toggle Summary Jaguar Health Achieves Statistically Significant Top Line Results in Study Evaluating Crofelemer for Treatment of Diarrhea Related to Targeted Cancer Therapy
Preclinical Study Results Expected to Provide Key Supportive Data for Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Targeted Cancer Therapy SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2019 / Jaguar Health, Inc.
Toggle Summary Jaguar Health Appoints Carol Lizak Chief Accounting Officer
SAN FRANCISCO, CA / ACCESSWIRE / August 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has promoted
Toggle Summary Jaguar Health, Inc. Reports 2019 Second Quarter Financial Results
Mytesi ® Net Sales and Gross Mytesi ® Sales Grew 102% and 93%, Respectively, in Q2 2019 Compared to Q2 2018 SAN FRANCISCO, CA / ACCESSWIRE / August 14, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel,
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Launches Updated Mytesi.com Website
SAN FRANCISCO, CA / ACCESSWIRE / August 7, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that the Company’s wholly-owned,
Toggle Summary Jaguar Health's CDMO Improves Manufacturing Processes to Support the Expanded Crofelemer Manufacturing Volume Expected to be Required for Potential Expanded Indications, Including a Potential Indication for Cancer Therapy-related Diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / August 2, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that Indena S.p.A., one of the two
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event at 3 p.m. Eastern Today
SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that the Company’s wholly-owned,
Toggle Summary Jaguar Health Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
SAN FRANCISCO, CA / ACCESSWIRE / July 23, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the closing of an underwritten
Toggle Summary Jaguar Health Announces Pricing of $14.4 Million Underwritten Public Offering
SAN FRANCISCO, CA / ACCESSWIRE / July 19, 2019 /  Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the pricing of an underwritten
Toggle Summary Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $4.4 Million
Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / July 15, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products
Toggle Summary Jaguar Health's Wholly Owned Subsidiary, Napo Pharmaceuticals, Inc., Commits to Support Study Evaluating the Effect of Crofelemer on Patients With Chronic Idiopathic Diarrhea
SAN FRANCISCO, CA / ACCESSWIRE / July 11, 2019 /  Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that its wholly owned subsidiary,
Toggle Summary Jaguar Health Strengthens Company's Balance Sheet by Reducing Approximately $10.5 Million of Debt Incurred to Effect 2017 Merger to Approximately $5.7 Million
Maturity Date of Remaining Merger-related Debt is December 31, 2020 SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2019 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products
Toggle Summary Jaguar Health Engages Integrium, LLC to Support Clinical Study Evaluating the Effect of Mytesi on the Microbiome
Study will Examine the Possible Benefits of Mytesi ® on Gut Health, Including Bloating and Abdominal Discomfort, in People Living with HIV SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company
Toggle Summary Jaguar Health Announces Key Finding for Final Canalevia Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs
Target Animal Safety Study Results Indicate Canalevia ™ NOAEL (No-Observed-Adverse-Effect Level) is Approximately Six Times Greater than Previously Demonstrated and that Canalevia is Also Safe for Use in Puppies SAN FRANCISCO, CA / ACCESSWIRE / June 19, 2019 / Jaguar Health, Inc.
Toggle Summary Jaguar Health Announces Completion of Pilot Study in Dogs in Support of Future Clinical Investigations Evaluating Crofelemer for Treatment of Noninfectious Diarrhea in Human Cancer Patients Receiving Tyrosine Kinase Inhibitors
SAN FRANCISCO, CA / ACCESSWIRE / June 18, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that a nonclinical pilot study to
Toggle Summary Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication
SAN FRANCISCO, CA / ACCESSWIRE / June 11, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that Jaguar's wholly-owned
Toggle Summary Jaguar Health, Inc. Announces 1-for-70 Reverse Stock Split
Shares of Common Stock to Begin Trading on Split-Adjusted Basis on June 7, 2019 SAN FRANCISCO, CA / ACCESSWIRE / June 6, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal
Toggle Summary Jaguar Health CEO and Board Members Invest in Bridge Financing
SAN FRANCISCO, CA / ACCESSWIRE / June 5, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that Lisa Conte, Jaguar's president
Toggle Summary Jaguar Health Refinances $10.5 Million of Secured Debt, Including an Extension of the Maturity of Such Debt from December 31, 2019 to December 31, 2020
SAN FRANCISCO, CA / ACCESSWIRE / June 3, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has received a
Toggle Summary Jaguar Health Eliminates More Than $6.4 Million in Secured Promissory Notes to Strengthen Company's Balance Sheet
SAN FRANCISCO, CA / ACCESSWIRE / May 29, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has extinguished
Toggle Summary Jaguar Health, Inc. Reports Voting Results from May 24, 2019 Annual Meeting of Stockholders
SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the voting results from the
Toggle Summary Jaguar Health, Inc. Reports 2019 First Quarter Financial Results
Mytesi ® Net Sales and Gross Sales Grew 154% and 161%, Respectively, in Q1 2019 Compared to Q1 2018 SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably
Toggle Summary Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
SAN FRANCISCO, CA / ACCESSWIRE / April 25, 2019 /  Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company is donating
Toggle Summary Jaguar Health, Inc. Reports 2018 Fourth Quarter and Year End Financial Results
Mytesi ® Gross Sales and Net Sales Grew 237% and 185%, Respectively, in the Year End 2018 Compared to Year End 2017 SAN FRANCISCO, CA / ACCESSWIRE / April 10, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi
SAN FRANSISCO, CA / ACCESSWIRE / April 2, 2019 /  Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc.
Toggle Summary Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for Mytesi
SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2019 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company is scheduled to
Toggle Summary Jaguar Completes Filing of CMC Technical Section with FDA for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs
SAN FRANCISCO, CA / ACCESSWIRE / March 20, 2019 /  Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has completed the
Toggle Summary Jaguar Health, Inc. Reports Voting Results from February 28, 2019 Special Meeting of Stockholders
All Proposals Approved SAN FRANCISCO, CA / ACCESSWIRE / March 5, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the
Toggle Summary Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Thursday, February 28, 2019
SAN FRANCISCO, CA / ACCESSWIRE / February 25, 2019 /  Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that its Special Meeting
Toggle Summary With the Addition of Mytesi to the Formulary for Florida's AIDS Drug Assistance Program (ADAP), Approximately 86% of ADAP-Eligible US Lives Now Have Access to Jaguar Health's FDA-Approved Drug Product
SAN FRANCISCO, CA / ACCESSWIRE / January 24, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that Mytesi ® (crofelemer)
Toggle Summary Jaguar Health to Present at Noble Capital Markets Annual Investor Conference January 28 in Fort Lauderdale
SAN FRANCISCO, CA / ACCESSWIRE / January 22, 2019 /  Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that it will be presenting
Toggle Summary Jaguar Health Receives First Order for First-Generation of Equilevia, the Company's Non-Prescription, Personalized, Premium Product for Total Gut Health in High-Performance Equine Athletes
SAN FRANCISCO, CA / ACCESSWIRE / January 9, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that a leading equine
Toggle Summary Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates
Napo Pharmaceuticals, Inc., Jaguar's Wholly-owned Human Health Subsidiary, Expected to Achieve 40% Net Sales Growth for Mytesi® (Crofelemer) in Q4'18 Versus Q3'18 SAN FRANCISCO, CA / ACCESSWIRE / January 7, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage
Toggle Summary Jaguar Health to Present at Biotech Showcase 2019 in San Francisco
SAN FRANCISCO, CA / ACCESSWIRE / January 3, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that Lisa Conte, Jaguar's
Toggle Summary Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance
SAN FRANCISCO, CA / ACCESSWIRE / January 2, 2019 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that Company management will
Toggle Summary Jaguar Health, Inc. Engages T.R. Winston & Company to Advise on Collaboration, Licensing and Development Activities Related to Mytesi and Crofelemer
SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that it has engaged T.R.
Toggle Summary Jaguar Health, Inc. Reports Third-Quarter 2018 Results
Mytesi ® Gross Sales and Net Sales Grew 36% and 28%, Respectively, in the Third Quarter of 2018 Compared to the Second Quarter of 2018 Company to Host Conference Call Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to Review Third-Quarter Results and Provide Updates Regarding Mytesi ®
Toggle Summary Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th
Company to Host Conference Call Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to Review Q3 Results and Provide Updates Regarding Mytesi ® Commercial, Educational & Product Development Activities SAN FRANCISCO, CA / ACCESSWIRE / November 13, 2018 / Jaguar Health, Inc.
Toggle Summary Jaguar Health, Inc. Expects to File Third-Quarter 2018 Financial Results November 14th
Company to Host Conference Call Thursday, November 15, 2018 at 8:00 a.m. Eastern Time to Review Q3 Results and Provide Updates Regarding Mytesi ® Commercial, Educational & Product Development Activities SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2018 / Jaguar Health, Inc.
Toggle Summary Jaguar Health, Inc. to Host Investor Meetings at Dawson James Small Cap Growth Conference Tuesday, October 30, 2018 in Jupiter, Florida
SAN FRANCISCO, CA / ACCESSWIRE / October 24, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced that its president and CEO,
Toggle Summary Jaguar Health Announces Pricing of $9 Million Underwritten Public Offering
SAN FRANCISCO, CA / ACCESSWIRE / October 2, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, today announced the pricing of an underwritten
Toggle Summary Knight Therapeutics and Jaguar Health Announce Strategic Partnership
Knight Therapeutics and Jaguar Health Announce Strategic Partnership Knight Receives License to Mytesi ® and Related Products in Canada and Israel MONTREAL, QC and SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2018 / Knight Therapeutics Inc. (TSX: GUD) (" Knight"), a Canadian-based specialty
Toggle Summary New Analysis of Data in Over 21,000 People Living with HIV Shows Diarrhea Continues to be an Issue and Has Not Declined Significantly Over Time
Results Reported at the 22 nd International AIDS 2018 Conference in Amsterdam, Netherlands SAN FRANCISCO, CA / ACCESSWIRE / July 24, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used
Toggle Summary Napo Pharmaceuticals to Present New Data at the 22nd International AIDS 2018 Conference
Presentation Will Cover New Data on the Incidence and Prevalence of Diarrhea in HIV Clinical Trials in the Recent Post-Combined Antiretroviral Therapy (cART) Era SAN FRANCISCO, CA / ACCESSWIRE / July 16, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing
Toggle Summary Jaguar Health, Inc. Provides Second Quarter 2018 Financial Updates
Napo Pharmaceuticals, Inc., Jaguar's wholly-owned human health subsidiary, achieved 47% gross sales growth for Mytesi ® (crofelemer) in the second quarter of 2018 versus the first quarter of 2018 SAN FRANCISCO, CA / ACCESSWIRE / July 12, 2018 / Jaguar Health, Inc.
Toggle Summary Jaguar Health (NASDAQ: JAGX) Subsidiary Napo Pharmaceuticals and RedHill Biopharma Enter U.S. Co-Promotion Agreement for Mytesi, Napo's FDA-Approved Drug Product
RedHill (NASDAQ: RDHL) has been granted the exclusive right to co-promote Mytesi ® (crofelemer 125 mg delayed-release tablets) to certain gastroenterologists and primary care physicians for the approved indication in people living with HIV/AIDS by Napo Pharmaceuticals Mytesi ® is an FDA-approved
Toggle Summary Jaguar Health Appoints Pharmaceutical Industry Veteran David MacNaughtan to Board of Directors
Separately, Jaguar has received notification that the Company is now in compliance with NASDAQ's listing standards SAN FRANCISCO, CA / ACCESSWIRE / June 20, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on
Toggle Summary Jaguar Health Appoints Senior Commercial Pharmaceutical Executive Greg Divis to Board of Directors
SAN FRANCISCO, CA / ACCESSWIRE / June 18, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has
Toggle Summary Napo Pharmaceuticals Presents New Data at the 13th International Conference on HIV Treatment and Prevention Adherence Regarding the Use of Mytesi (Crofelemer) to Treat Noninfectious Diarrhea in HIV Patients
The presentation reported the findings on measures of physical and social function as well as work productivity, which revealed statistically significant improvements in several of the measures SAN FRANCISCO, CA / ACCESSWIRE / June 12, 2018 /  Napo Pharmaceuticals, Inc.
Toggle Summary Jaguar Health, Inc. Announces 1-for-15 Reverse Stock Split
SAN FRANCISCO, CA / ACCESSWIRE / June 1, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) (''Jaguar'' or the ''Company''), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the
Toggle Summary Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals
Mr. Griffing to Lead Commercialization Efforts for Mytesi, Jaguar's FDA-Approved, First-in-Class Drug Product SAN FRANCISCO, CA / ACCESSWIRE / May 29, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on
Toggle Summary Jaguar Health, Inc. Reports First-Quarter 2018 Operational Updates and Voting Results from 2018 Annual Meeting of Stockholders
Company Management to Host Conference Call Monday, May 21 st at 4:30 p.m. Eastern Time for Investors and Analysts SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on
Toggle Summary ''Under Pressure'' Episode of Merce Uses Comedy to Help People Living with HIV Talk About Diarrhea
Merce  Series Creator and Cast Members Will Appear with Napo Pharmaceuticals, the Lead Sponsor of  Merce  Season 2, at AIDS Walk New York in Central Park on May 20, 2018 SAN FRANCISCO, CA / ACCESSWIRE / May 15, 2018 /  Napo Pharmaceuticals, Inc. (Napo), a human health company developing and
Toggle Summary Experts Highlight that Immune System Activation in Aging Patients Living with HIV/AIDS Triggers Effects Such as "Leaky Gut", Which Can Lead to Diarrhea
Mytesi for HIV-related Diarrhea Now on ADAP Formularies in 22 States SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived
Toggle Summary Jaguar Subsidiary Napo Pharmaceuticals Signs Agreement with the ADAP Crisis Task Force for Mytesi
Agreement Provides Pricing for Mytesi to Each U.S. State's AIDS Drug Assistance Program (ADAP) - Organizations that Provide HIV-related Services and Approved Medications to More than Half a Million People Annually SAN FRANCISCO, CA / ACCESSWIRE / April 10, 2018 /  Jaguar Health, Inc.
Toggle Summary Recent Publications Indicate that Diarrhea is a Significant and Serious Issue in HIV
Article in the Journal AIDS Care Shows That Patients with Diarrhea Have Poor Adherence to Their Antiretroviral Therapy (ARV) Regimen SAN FRANCISCO, CA / ACCESSWIRE / April 9, 2018 / Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal
Toggle Summary Jaguar Health Appoints Jonathan B. Siegel to Board of Directors
SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that it has
Toggle Summary Jaguar Health Announces Up to $16.2 Million in Equity Financings in Separate Private Placement Investments, Including Investment by Sagard Capital Partners, L.P., to Continue Commercialization of FDA-Approved Mytesi
Largest Investor Locked in for 12 Months SAN FRANCISCO, CA / ACCESSWIRE / March 26, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a
Toggle Summary FDA Indicates that Jaguar's Reasonable Expectation of Effectiveness Technical Section is Complete for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs
SAN FRANCISCO, CA / ACCESSWIRE / March 8, 2018 /  Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the U.S.
Toggle Summary Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program
Toggle Summary Jaguar Health Provides Updates Regarding Commercial, Educational & Product Development Programs and 2017 Results for Mytesi Since Merger (August–December 2017)
Mytesi Sales Increased 17.71% Each Month Over the Prior Month SAN FRANCISCO --(BUSINESS WIRE)--Jan. 22, 2018-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal
Toggle Summary Jaguar Health to Host Conference Call Monday, January 22nd at 4:15 p.m. Eastern Time to Provide Updates Regarding Jaguar and Napo Pharmaceuticals Commercial, Educational & Product Development Activities and 2017 Results
SAN FRANCISCO --(BUSINESS WIRE)--Jan. 18, 2018-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global
Toggle Summary Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim
SAN FRANCISCO --(BUSINESS WIRE)--Jan. 18, 2018-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc.
Toggle Summary Jaguar Health and Dubai-based Seed Mena Enter Collaboration Agreement for Equilevia, Jaguar’s Personalized, Premium Product for Total Gut Health and Wellness in Horses
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 14, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis,
Toggle Summary New Survey Finds People Living With HIV With Diarrhea Often Suffer in Silence
A change in the way doctors and patients talk about symptoms could better address this neglected comorbidity in HIV SAN FRANCISCO --(BUSINESS WIRE)--Dec. 12, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products
Toggle Summary Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 1, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global
Toggle Summary Keep Your Pants On Campaign From Napo Pharmaceuticals Chosen as Best HIV-Related Awareness Campaign of 2017 by Healthline
Campaign designed to raise awareness of the issue of diarrhea among people with HIV/AIDS and encourage them to speak with their healthcare providers SAN FRANCISCO --(BUSINESS WIRE)--Dec. 1, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel
Toggle Summary Jaguar Health Enters Share Purchase Agreement for 2 Million Shares and Common Stock Purchase Agreement Relating to a 10 Million Share Equity Line Offering With L2 Capital, LLC
Registered Direct at $0.25 Per Share and Equity Line at Fixed Price of $0.52 Per Share SAN FRANCISCO --(BUSINESS WIRE)--Nov. 27, 2017-- Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably
Toggle Summary Jaguar Health Files First Quarterly Earnings Report Since July 2017 Merger with Napo Pharmaceuticals
As a Result of the Merger, Jaguar Shows Positive Net Income for Q3 2017 SAN FRANCISCO --(BUSINESS WIRE)--Nov. 20, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived
Toggle Summary Dr. Roscoe M. Moore Jr., DVM, MPH, Ph.D., DSc Joins Napo Pharmaceuticals Scientific Advisory Board for HIV for Mytesi, Napo’s FDA-Approved Human Prescription Drug
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 15, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis,
Toggle Summary Year-to-Date Gross Sales for Mytesi, the FDA-Approved Human Prescription Drug Product of Jaguar Health’s Wholly-Owned Subsidiary, Napo Pharmaceuticals, Total $2.8 Million
Expansion of National Salesforce Continues for Mytesi as Napo Significantly Ramps Up Post-Merger Product Commercialization and Launch Activities in Response to Impact of Over 50% Sales Growth Since Merger SAN FRANCISCO --(BUSINESS WIRE)--Nov. 14, 2017-- Jaguar Health, Inc.
Toggle Summary Today’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time
First Post-Merger Earnings Call for Jaguar and its Wholly-Owned Subsidiary, Napo Pharmaceuticals , Regarding Sales of Napo’s FDA-Approved Human Drug, Mytesi, an Antidiarrheal Indicated for the Symptomatic Relief of Noninfectious Diarrhea in Adult Patients with HIV/AIDS on Antiretroviral Therapy SAN
Toggle Summary Jaguar Health to Host Earnings Conference Call Tuesday, November 14th at 4:30 p.m. Eastern Time
First Post-Merger Earnings Call for Jaguar and its Wholly-Owned Subsidiary, Napo Pharmaceuticals , Regarding Sales of Napo’s FDA-Approved Human Drug, Mytesi, an Antidiarrheal Indicated for the Symptomatic Relief of Noninfectious Diarrhea in Adult Patients with HIV/AIDS on Antiretroviral Therapy SAN
Toggle Summary Jaguar Health Enters Non-Binding Agreement of Terms to Issue a Secured Convertible Note to Iliad Research and Trading, L.P. (an Affiliate of Chicago Venture Partners, L.P.), as Jaguar Expands Commercial Efforts for Mytesi
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 8, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar"), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis,
Toggle Summary Jaguar Health Receives Approval from The American Association of Veterinary State Boards RACE Committee for Continuing Education Program for Veterinarians and Veterinary Technicians on Diarrhea in Foals
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 7, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis,
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napo’s FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug
Site Provides Information and Resources for Consumers as Well as HIV Physicians, Gastroenterologists and Other Healthcare Professionals SAN FRANCISCO --(BUSINESS WIRE)--Nov. 1, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Launches National “Keep Your Pants On… Unless You Don’t Want To” Campaign to Highlight the Need to Recognize and Treat Diarrhea in People Living With HIV/AIDS
Campaign Kicks Off with Events at AIDS Walk Los Angeles and Greater Palm Springs Pride as Well as Digital Ads on More Than 25 HIV/LGBT Media Outlets SAN FRANCISCO --(BUSINESS WIRE)--Oct. 26, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Establishes Scientific Advisory Boards for Planned Follow-on Indications for Mytesi, Napo’s FDA-approved Human Prescription Drug
Leading Medical Oncologist and Hematologist Dr. Lee Schwartzberg Joins Mytesi Scientific Advisory Board for Cancer Therapy-Related Diarrhea (CTD)—An Area of Significant Concern for Diarrhea Management in the Era of Novel Targeted Agents Such as Recently Approved CDK 4/6 and Tyrosine Kinase
Toggle Summary Napo Pharmaceuticals Endorses Prevention Access Campaign’s U=U Consensus Statement for People Living With HIV/AIDS (PLWHA)
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 18, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc.
Toggle Summary Jaguar Health Prices $4.25 Million Public Offering of Common Stock
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 29, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a
Toggle Summary Jaguar Subsidiary Napo Pharmaceuticals Files CMC Supplement with FDA for Sample-Size Bottles of Mytesi, Napo’s FDA-Approved Human Drug, to Support Upcoming National Sample Campaign
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 28, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably-derived gastrointestinal products for both human prescription use and veterinary use on a global
Toggle Summary Jaguar Subsidiary Napo Pharmaceuticals and Glenmark Pharmaceuticals Sign Agreement Returning Key Rights in 141 Countries to Napo, Solidifying Jaguar’s Global Commercial Control of Mytesi (Crofelemer), Jaguar’s FDA-Approved Human Drug
Glenmark Will Continue to Serve as the cGMP-compliant Commercial Manufacturer of Crofelemer for Jaguar and Napo at its FDA-Approved Facilities in India Agreement Also Provides Napo with Commercial Rights to the Existing Regulatory Approvals for Crofelemer in Brazil , Ecuador , Zimbabwe & Botswana
Toggle Summary FDA Indicates That Jaguar’s Canalevia Drug Product Candidate Qualifies as “Minor Use” for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication
Jaguar Expects to Conduct the Commercial Launch of Canalevia in the First Half of 2018 for EID and CID (Chemotherapy-Induced Diarrhea) in Dogs, Dependent on Receiving Conditional Approval for These Indications SAN FRANCISCO --(BUSINESS WIRE)--Sep. 20, 2017-- Jaguar Health, Inc.
Toggle Summary Advocates Tez Anderson and Josh Robbins to Host Facebook Live Conversation on HIV/AIDS and Aging Awareness Day to Discuss Issues Affecting Long Term Survivors
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 18, 2017-- (NASDAQ: JAGX) – Today marks National HIV/AIDS and Aging Awareness Day (NHAAD), observed annually to focus on the challenges facing the aging population with regards to HIV prevention, testing, care and treatment.
Toggle Summary Jaguar Health Announces Proposed Public Offering of Common Stock
Maxim Group and Jaguar to Host Web Presentation Wednesday, September 20 th at 2 p.m. Eastern Time SAN FRANCISCO --(BUSINESS WIRE)--Sep. 18, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), a natural-products pharmaceuticals company focused on developing and commercializing
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Expands Mytesi Salesforce With Hire of Experienced HIV & GI Drug Sales Reps in Key U.S. Markets
New Reps Will Target Physicians and Gastroenterologists Who Treat Large Numbers of HIV Patients SAN FRANCISCO --(BUSINESS WIRE)--Sep. 15, 2017-- Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably
Toggle Summary New Survey Ranks Diarrhea as Number One Gastrointestinal Complaint of HIV/AIDS Patients
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 12, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, and a wholly-owned subsidiary of Jaguar Health, Inc.
Toggle Summary Jaguar Health Company Name Now Updated on Nasdaq.com Post-Merger
Jaguar’s Post-Merger Market Cap Expected to be Updated on Nasdaq.com and Other Web-based Financial Data Platforms Later this Month SAN FRANCISCO --(BUSINESS WIRE)--Aug. 16, 2017-- Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and
Toggle Summary Jaguar Health Subsidiary Napo Pharmaceuticals Receives Orphan-Drug Designation for Mytesi (crofelemer) for Treatment of Short Bowel Syndrome
Napo Appoints Veteran Pharmaceutical Sales Leader to Head National Sales SAN FRANCISCO --(BUSINESS WIRE)--Aug. 7, 2017-- Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustainably derived gastrointestinal
Toggle Summary The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective
The Combined Company’s New Name is Jaguar Health, Inc. Nasdaq Ticker Remains the Same: JAGX Merger Terms Include Additional Funding for Combined Company at $0.925/share as Disclosed in the Proxy/Prospectus SAN FRANCISCO--( BUSINESS WIRE )--The merger of Jaguar Animal Health, Inc.
Toggle Summary Stockholders of Jaguar Animal Health and Napo Pharmaceuticals Vote to Approve Merger
Merger Terms Include Funding for Combined Company and Other Aspects of the Merger Disclosed in the Proxy/Prospectus Jaguar to Host Conference Call Friday, July 28th at 8:30 a.m. Eastern Time SAN FRANCISCO --(BUSINESS WIRE)--Jul. 27, 2017-- Jaguar Animal Health, Inc.
Toggle Summary New Data Shows Dramatic Reduction in Chronic Diarrhea Episodes with Crofelemer (Mytesi) Treatment
Results Reported at 9th International AIDS Society (IAS) Conference on HIV Science in Paris, France Over 7 Million Patients with HIV Worldwide May Benefit from the Reduction in Diarrhea Achieved with Long-Term Mytesi Therapy SAN FRANCISCO --(BUSINESS WIRE)--Jul.
Toggle Summary Jaguar Neonorm Foal Study Accepted for Publication in Veterinary Journal
SAN FRANCISCO --(BUSINESS WIRE)--Jul. 18, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, and Napo
Toggle Summary Jaguar Animal Health to Hold Special Meeting of Stockholders July 27, 2017 to Vote Upon the Consummation of its Proposed Merger with Napo Pharmaceuticals, Inc.
Terms of Proposed Merger Include Funding for Combined Company and Other Aspects of the Merger Disclosed in the Proxy/Prospectus Jaguar to Host Conference Call Friday, July 28th at 8:30 a.m. Eastern Time SAN FRANCISCO --(BUSINESS WIRE)--Jul. 6, 2017-- As previously announced, Jaguar Animal Health,
Toggle Summary Napo Pharmaceuticals to Present New Crofelemer (Mytesi) Data at International Aids Society Conference on HIV Science
Presentation will cover new data on the long-term efficacy of crofelemer (Mytesi®) based on a supplemental analysis of the ADVENT trial SAN FRANCISCO --(BUSINESS WIRE)--Jun. 27, 2017-- Napo Pharmaceuticals, Inc. , a human health company developing and commercializing novel gastrointestinal
Toggle Summary Jaguar Animal Health’s Neonorm Calf Obtains OMRI Listing and Can Now be Used in Production of Certified Organic Dairy and Beef Cattle
SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that the Organic
Toggle Summary Jaguar Animal Health Launches Commercial Website for Neonorm Foal & Neonorm Calf
Neonorm.com allows online ordering and features in-depth product information for dairy and beef farmers, foal owners and veterinarians to help drive sales SAN FRANCISCO --(BUSINESS WIRE)--Jun. 7, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on
Toggle Summary Jaguar Animal Health and Napo Pharmaceuticals Announce Filing of Two Orphan Drug Designation Applications with FDA for Mytesi for Serious Unmet Medical Needs
Napo Applications Request Orphan Drug Designation for Mytesi for Congenital Diarrheal Disorders and Diarrhea Associated with Short Bowel Syndrome Pursuit of Orphan Drug Designations Parallels Jaguar’s Focus on MUMS (Minor Use and Minor Species) Indications for Canalevia in Dogs SAN FRANCISCO
Toggle Summary Lisa Conte, CEO of Jaguar Animal Health and Napo Pharmaceuticals, to Present at the Southern California Investment Forum May 31, 2017 in Los Angeles
Management will be available for meetings during this luncheon and networking event SAN FRANCISCO --(BUSINESS WIRE)--May 25, 2017-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for
Toggle Summary Napo Pharmaceuticals’ New Mytesi Video Calls Attention to the Continuing Widespread Problem of Diarrhea in People Living With HIV/AIDS
SAN FRANCISCO --(BUSINESS WIRE)--May 24, 2017-- Napo Pharmaceuticals, Inc. (Napo), a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas, which launched Mytesi ® in April, 2017, and Jaguar Animal Health,
Toggle Summary Jaguar Animal Health and Napo Pharmaceuticals Appoint Dr. Pravin Chaturvedi to Chair Scientific Advisory Board
Jaguar and Napo Comment on Potential Follow-on Indications for Mytesi, Napo’s “Pipeline Within a Product” SAN FRANCISCO --(BUSINESS WIRE)--May 10, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class
Toggle Summary Jaguar Signs Distribution Agreement for Japan for Neonorm Foal & Neonorm Calf
Jaguar Receives Extension of Nasdaq Listing SAN FRANCISCO --(BUSINESS WIRE)--Apr. 28, 2017-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals,
Toggle Summary Jaguar and Napo Issue Commercial Updates
Jaguar Kicks Off Neonorm Foal TV Campaign & Neonorm Calf Radio Campaign Sales of Neonorm Calf by Jaguar’s Distributor ANIMART Up 167% in February 2017 Compared to February 2016 Napo Launches National Sales Force for Mytesi Mytesi Study Abstract Selected for Presentation as Poster Exhibition at
Toggle Summary Jaguar Animal Health and Napo Pharmaceuticals Enter Definitive Merger Agreement
Merger Will Provide an Important Revenue Stream to Jaguar from Mytesi, an FDA Approved Napo Anti-Diarrheal Launched October 2016 Offering a First-in-Class, Novel Mechanism of Action Highly Conserved Across All Mammals SAN FRANCISCO --(BUSINESS WIRE)--Mar. 31, 2017-- Napo Pharmaceuticals, Inc.
Toggle Summary Jaguar Enters Exclusive Evaluation Period With Multinational Animal Health Pharmaceutical Firm Regarding Equilevia, Jaguar’s Drug Product Candidate for Equine Gastric Ulcer Syndrome
SAN FRANCISCO --(BUSINESS WIRE)--Mar. 28, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that
Toggle Summary Jaguar Animal Health Seeks MUMS Designation for Canalevia for Exercise-Induced Diarrhea in Dogs
SAN FRANCISCO --(BUSINESS WIRE)--Mar. 14, 2017-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (Jaguar), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that it
Toggle Summary Jaguar Animal Health to Participate in 29th Annual ROTH Conference the Week of March 13th in Orange County, California
Management will be available to schedule meetings during the conference SAN FRANCISCO --(BUSINESS WIRE)--Mar. 3, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and
Toggle Summary Napo Pharmaceuticals Signs Agreement with Alamo Pharma Services to Launch National Sales Force for Mytesi
National Sales Force Will Promote and Provide Samples of Mytesi™ to HIV Healthcare Providers SAN FRANCISCO--( BUSINESS WIRE )--Napo Pharmaceuticals, Inc., a company focused on the development and commercialization of proprietary pharmaceuticals for the global marketplace from plants traditionally
Toggle Summary Study Supporting Herd-wide Reduction in Incidence and Severity of Diarrhea With Prophylactic Use of Neonorm Calf Published in Journal of Dairy Science
Study Conducted in Association with Cornell University College of Veterinary Medicine and Demonstrates Significant Benefits Jaguar Plans to Launch the Prophylactic Formulation of Neonorm Calf this Year in Powder Form for Administration in Liquid SAN FRANCISCO --(BUSINESS WIRE)--Feb.
Toggle Summary Jaguar Animal Health Enters Binding Agreement of Terms to Merge with Napo Pharmaceuticals
Merger Will Provide an Important Revenue Stream to Jaguar from Mytesi ™ , an FDA Approved Anti-Diarrheal Launched October 2016 that Offers a First-in-Class, Novel Mechanism of Action Jaguar to Host Investor Call Thursday, February 9th at 9:00 a.m. ET SAN FRANCISCO --(BUSINESS WIRE)--Feb.
Toggle Summary Jaguar Animal Health Begins Entry Into Organic Market With Neonorm Calf
SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (NASDAQ: JAGX) ("Jaguar"), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that it has begun
Toggle Summary Jaguar Animal Health, Elanco Enter Global Collaboration for Development, Co-Promotion of Canalevia
Agreement provides Elanco with license rights to Jaguar’s crofelemer-based drug product candidates for treatment of diarrhea in dogs and other companion animals Jaguar Animal Health to host investor call on Tuesday, January 31st at 9:00 a.m. ET SAN FRANCISCO --(BUSINESS WIRE)--Jan.
Toggle Summary Jaguar Animal Health to Participate in Biotech Showcase 2017 Week of January 9th in San Francisco
Management will also be available to schedule meetings outside of the conference SAN FRANCISCO --(BUSINESS WIRE)--Jan. 5, 2017-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for
Toggle Summary Jaguar Animal Health Appoints Dr. Ari Azhir to Board of Directors
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 19, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that
Toggle Summary Jaguar Animal Health and Henry Schein, Inc. Sign Exclusive Distribution Agreement for Neonorm Foal
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 12, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, today announced that
Toggle Summary Jaguar Animal Health Exhibits Neonorm Foal at American Association of Equine Practitioners Annual Convention
Jaguar Also Hosted a Dinner Discussion Gathering During AAEP with Equine Veterinarian Opinion Leaders in Support of the Company’s Clinical Development Efforts SAN FRANCISCO --(BUSINESS WIRE)--Dec. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on
Toggle Summary Jaguar Animal Health Announces Private Placement of Common Stock and Warrants
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 23, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced today that
Toggle Summary Jaguar Animal Health Issues Racing Data Summary for Horses Participating in the Company’s Recently Completed Dose Determination Study for its Drug Product Candidate for Equine Gastric Ulcer Syndrome
A Full Analysis of the Study Data with Scoring of Squamous and Glandular Ulcers is Expected to be Available in January SAN FRANCISCO --(BUSINESS WIRE)--Nov. 14, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing
Toggle Summary Jaguar Animal Health Announces Final Topline Results for Proof-of-Concept Study for Secretory Diarrhea in Dogs
Statistically Significant Final Results Confirm Interim Conclusion That Crofelemer Treatment is Superior to Placebo SAN FRANCISCO --(BUSINESS WIRE)--Oct. 18, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and commercializing first-in-class
Toggle Summary Jaguar Animal Health and Napo Pharmaceuticals Announce Details for Proposed Merger
Merger Would Allow Jaguar to Recognize an Important Revenue Stream from First-in-Class, Novel Mechanism of Action of the Anti-diarrheal Mytesi SAN FRANCISCO --(BUSINESS WIRE)--Oct. 6, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar”), an animal health company focused on developing and
Toggle Summary Jaguar Animal Health Signs Exclusive Distribution Agreement for Croton lechleri Botanical Extract for Pigs and Dairy Cattle in the Chinese Marketplace
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 7, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary Jaguar Animal Health Announces Additional Topline Results from Study of Second-Generation Formulation of Neonorm Calf Conducted in Association with Cornell University College of Veterinary Medicine
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 1, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary Jaguar Animal Health Announces Positive Preliminary Topline Results of Two Chinese-sponsored Farm Studies to Evaluate the Safety and Effectiveness of Neonorm Botanical Extract in Piglets
High resolution in treated animals versus high mortality in control piglets, 1-3 days old Jaguar has entered into negotiations for a potential exclusive distribution relationship for pigs and dairy cattle in the Chinese marketplace with the China-based business entity involved in conducting these
Toggle Summary Jaguar Animal Health Appoints Leading Oncologist and Drug Development Executive as Chief Scientific Officer
Dr. Roger Waltzman to Lead Development Teams for Jaguar’s SB-300 and Canalevia Drug Product Candidates SAN FRANCISCO --(BUSINESS WIRE)--Jun. 30, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing
Toggle Summary Jaguar Animal Health Announces Positive Topline Results of University Study of Second-Generation Formulation of Neonorm Calf and Commercialization Strategy Updates
Advances commercialization strategy for equine and companion animal drug product candidates SAN FRANCISCO --(BUSINESS WIRE)--Jun. 17, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class
Toggle Summary Jaguar Animal Health Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
SAN FRANCISCO --(BUSINESS WIRE)--Jun. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary Jaguar Animal Health Initiates Dose Determination Study with the Target Commercial Paste Formulation of SB-300, the Company’s Drug Product Candidate for Treatment of Equine Gastric Ulcer Syndrome
SAN FRANCISCO --(BUSINESS WIRE)--May 4, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary SB-300, Jaguar’s Drug Product Candidate for the Treatment of Gastric Ulcers, Enables Continued Therapy in Performance Horses in Accordance with Standard Testing Guidelines
Results of Initial Study Show that Jaguar’s Equine Product Candidate for Treatment of Gastric Ulcers May Offer Horse Owners an Additional Advantage in the Competition Horse World, where Requirements Exist for Animals to Compete Free from the Effect of Any Drugs SAN FRANCISCO --(BUSINESS WIRE)--Apr.
Toggle Summary Jaguar Animal Health Obtains Protocol Concurrence From FDA for Canalevia Drug Product Candidate for Treatment of Acute Diarrhea in Dogs
SAN FRANCISCO --(BUSINESS WIRE)--Apr. 13, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary Jaguar Animal Health Appoints John Micek III to Board of Directors
SAN FRANCISCO --(BUSINESS WIRE)--Apr. 6, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses,
Toggle Summary Jaguar Animal Health Appoints Dr. Philippe Brianceau as Chief Veterinary Officer
SAN FRANCISCO --(BUSINESS WIRE)--Feb. 22, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced today the
Toggle Summary Jaguar’s SB-300 Drug Product Candidate in Development
Advantages as an Alternative Approach to the Management of Gastrointestinal Ulcers in Horses SAN FRANCISCO --(BUSINESS WIRE)--Feb. 16, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class
Toggle Summary Jaguar Animal Health, Inc. Announces Closing of Public Offering; Secures Funding Through Anticipated Launch of First Prescription Drug Product Candidate
Progress on Rx Product Pipeline SAN FRANCISCO --(BUSINESS WIRE)--Feb. 9, 2016-- Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, today announced the
Toggle Summary Jaguar Animal Health, Inc. Prices 2,000,000 Common Share Offering
SAN FRANCISCO , Feb. 3, 2016 /PRNewswire/ --   Jaguar Animal Health, Inc. (Nasdaq: JAGX) , an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced today the pricing of an
Toggle Summary Jaguar Animal Health Reports Topline Findings for its Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in Horses
SAN FRANCISCO --(BUSINESS WIRE)--Jan. 28, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced
Toggle Summary Jaguar Animal Health Initiates University Study to Further Investigate Possible Prophylactic and Prebiotic Benefits of a Second-Generation Formulation of Neonorm in Dairy Calves
SAN FRANCISCO --(BUSINESS WIRE)--Jan. 7, 2016-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Jaguar Animal Health Initiates Pivotal Field Study to Evaluate Safety and Effectiveness of Canalevia Drug Product Candidate for Treatment of Acute Diarrhea in Dogs
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 22, 2015-- Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced today that it has initiated a pivotal
Toggle Summary Jaguar Animal Health Announces Positive Results in University Pilot Safety Study of Crofelemer in Horses
Study is First Step in Jaguar’s Development Program for a Crofelemer Drug Product Candidate for Treatment of Diarrhea Associated with Acute Colitis in Horses SAN FRANCISCO --(BUSINESS WIRE)--Dec. 21, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health
Toggle Summary Jaguar Animal Health Announces Positive Results of Investigator-Initiated Follow-up Neonorm Study in Foals
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 18, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and horses, announced positive
Toggle Summary Jaguar Animal Health Appoints Karen Wright as Chief Financial Officer
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 16, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced
Toggle Summary Jaguar Animal Health Completes Enrollment for Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in Horses
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 15, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, and high-value horses, announced
Toggle Summary Jaguar Animal Health Initiates University Pilot Safety Study to Evaluate Use of Crofelemer for the Treatment of Diarrhea Associated with Acute Colitis in Horses
SAN FRANCISCO --(BUSINESS WIRE)--Dec. 3, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Jaguar Animal Health to Present at the 2015 LD Micro Conference on December 3rd in Los Angeles
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 23, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that Steven King ,
Toggle Summary Jaguar Animal Health Announces Positive Results from Proof-of-Concept Study of Neonorm in Foals
Product Launching at the American Association of Equine Practitioners Annual Convention December 5-9 th SAN FRANCISCO --(BUSINESS WIRE)--Nov. 16, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing
Toggle Summary Jaguar Animal Health Initiates Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in Horses
SAN FRANCISCO --(BUSINESS WIRE)--Nov. 5, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary University Study Supports Benefit of Jaguar Animal Health’s Neonorm Calf on Intestinal Microbiome in Pre-weaned Dairy Calves
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 27, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that a recently
Toggle Summary U.S. Patent and Trademark Office Issues Notices of Allowance in Two Pending NP-500 Patent Applications Licensed Exclusively by Jaguar Animal Health for Veterinary Use
NP-500 is the Active Pharmaceutical Ingredient in Jaguar’s Drug Product Candidates to Treat Diseases Related to Insulin-resistance in Dogs, Horses & Cats SAN FRANCISCO --(BUSINESS WIRE)--Oct. 26, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health
Toggle Summary Jaguar Animal Health to Host Analyst and Investor Day on November 16, 2015 in New York City
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 26, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it will host
Toggle Summary Jaguar Animal Health Signs Crofelemer Formulation Development and Manufacturing Contract with Patheon
Contract Secured in Preparation for Pivotal Trial & Expected Launch of Jaguar’s Prescription Drug Candidate, Canalevia, for Acute Diarrhea in Dogs Jaguar to Leverage Patheon’s Experience Manufacturing FDA-approved, Human-specific Formulation of Crofelemer SAN FRANCISCO --(BUSINESS WIRE)--Oct.
Toggle Summary Jaguar Animal Health Completes Second Neonorm Field Study Indicating Beneficial Effect of Product on Pre-Wean Weight Gain & Normalization of Stool Formation in Dairy Calves Beyond Current Standard of Care
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 7, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today the results of a
Toggle Summary Jaguar Animal Health to Present at the Aegis Capital 2015 Growth Conference
SAN FRANCISCO --(BUSINESS WIRE)--Oct. 2, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that Lisa Conte ,
Toggle Summary Jaguar Animal Health Signs Crofelemer Manufacturing & Supply Agreement with Glenmark Pharmaceuticals Ltd.
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 28, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Jaguar Animal Health Initiates Proof-of-Concept Study to Evaluate Safety, Tolerability & Efficacy of Neonorm in Foals
SAN FRANCISCO --(BUSINESS WIRE)--Sep. 25, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Study Evaluating Effect of Jaguar Animal Health’s Neonorm on Diarrhea in Newborn Dairy Calves Published in Journal of Dairy Science
Study Conducted at Cornell University College of Veterinary Medicine SAN FRANCISCO --(BUSINESS WIRE)--Sep. 2, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for
Toggle Summary Jaguar Animal Health to Attend the 2015 KC Animal Health Investment Forum
SAN FRANCISCO --(BUSINESS WIRE)--Aug. 25, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that Lisa Conte ,
Toggle Summary Jaguar Animal Health Secures Debt Financing
SAN FRANCISCO --(BUSINESS WIRE)--Aug. 19, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Jaguar Animal Health Submits All Required Major Technical Sections of New Animal Drug Application for Canalevia
Company Prepares for New Prescription Drug Launch in First Half of 2016 for Dogs Suffering from Chemotherapy-Induced Diarrhea SAN FRANCISCO --(BUSINESS WIRE)--Aug. 19, 2015-- Jaguar Animal Health, Inc. (NASDAQ: JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and
Toggle Summary KCSA Strategic Communications to Lead Investor Relations Program for Jaguar Animal Health
NEW YORK , July 16, 2015 /PRNewswire/ -- KCSA Strategic Communications, a prominent New York -based communications firm, announced today that it has been retained by Jaguar Animal Health, Inc. (NASDAQ: JAGX ) ("Jaguar" or the "Company"), an animal health company focused on developing and
Toggle Summary Jaguar Animal Health Appoints Dr. Victoria Lewis as Chief of Clinical Development
SAN FRANCISCO --(BUSINESS WIRE)--Jul. 7, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has
Toggle Summary Jaguar Completes Study in Dogs with Chemotherapy-Induced Diarrhea with Commercial Formulation of Canalevia
Jaguar Targeting First Prescription Product Launch in Early 2016 SAN FRANCISCO --(BUSINESS WIRE)--Jul. 1, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for
Toggle Summary Jaguar Animal Health, Inc. Added to Russell Microcap Index
SAN FRANCISCO --(BUSINESS WIRE)--Jun. 30, 2015-- Jaguar Animal Health, Inc. (Nasdaq:JAGX) (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it was added
Toggle Summary Jaguar Animal Health Field Study Confirms Beneficial Effect of Neonorm on Average Daily Weight in Calves
Results Support Study to Investigate Potential Prebiotic Effect on Calf Gut Microbiome SAN FRANCISCO --(BUSINESS WIRE)--Jun. 9, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion
Toggle Summary Jaguar Animal Health Appoints Industry Expert Folkert Kamphuis to Board of Directors
SAN FRANCISCO --(BUSINESS WIRE)--Jun. 3, 2015-- Jaguar Animal Health, Inc. (NASDAQ:JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has named Folkert Kamphuis to its board
Toggle Summary Jaguar Animal Health, Inc. Announces Pricing of Initial Public Offering
SAN FRANCISCO --(BUSINESS WIRE)--May 13, 2015-- Jaguar Animal Health, Inc. (Nasdaq: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today the pricing of its initial public offering of
Toggle Summary Jaguar Animal Health Files Two Provisional Patent Applications, Deepening its Pipeline of Proprietary Gastrointestinal Products for Animals
One Application Covers the Combined Use of Croton lechleri-derived Products and Rifaximin to Address Diarrhea Symptoms The Second is for the Prebiotic Benefit of Crofelemer and Croton lechleri-derived Products in Dairy Calves and Other Animals San Francisco, CA (March 4, 2015): Jaguar Animal
Toggle Summary Jaguar Animal Health Signs Agreement with Latin America’s Largest Veterinary Biotechnology Company
San Francisco, CA (February 26, 2015): Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has entered into a supply and distribution
Toggle Summary Jaguar Animal Health Announces Outcome of Canine Proof-of-Concept Study for Canalevia
Statistically Significant Results Support the Conclusion that Canalevia Treatment is Superior to Placebo 91.0% of Treated Dogs Achieved a Formed Stool During the Study Versus 50.0% of Placebo-treated Animals San Francisco, CA (February 19, 2015): Jaguar Animal Health, Inc.
Toggle Summary Jaguar Animal Health Files Ninth Investigational New Animal Drug Application
Drug Candidate Addresses Gastric, Intestinal and Colonic Ulcers in Horses and Foals San Francisco, CA (February 10, 2015): Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal and other proprietary health products
Toggle Summary Jaguar Animal Health Signs Distribution Agreement with Vedco and Kicks off National Neonorm Calf Marketing Campaign
Jaguar Exhibiting at World Ag Expo & Western Veterinary Conference this Month San Francisco, CA (February 5, 2015): Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production
Toggle Summary Jaguar Animal Health Initiates Filing of Its First New Animal Drug Application with FDA
Canalevia™ is a New Prescription Drug Candidate for Treatment of Dogs Undergoing Chemotherapy San Francisco, CA (December 22, 2014): Jaguar Animal Health, Inc., an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production
Toggle Summary Jaguar Animal Health Completes Equine Study for Safety & Palatability of Neonorm™ Foal Gastrointestinal Product
San Francisco, CA (December 4, 2014): Jaguar Animal Health, Inc. (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has completed a study designed to
Toggle Summary Jaguar Animal Health Appoints Former Merial Executive to Head Regulatory Affairs
San Francisco, CA (November 21, 2014): Jaguar Animal Health, Inc. (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has appointed Tim Dotson, a
Toggle Summary Jaguar Animal Health, Inc. Launches First Product, Neonorm™ Calf, at World Dairy Expo
ANIMART Named First Commercial Partner September 29, 2014 08:30 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--Today, Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and
Toggle Summary Jaguar Animal Health, Inc. Files Eighth Investigational New Animal Drug Application
SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal and other proprietary health products for companion and production animals, announced today that it has submitted its eighth
Toggle Summary Jaguar Animal Health Names VP, Commercial Operations
09:38 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc., (“Jaguar” or the “Company”) an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, today named Ian Parker, a
Toggle Summary Jaguar Files INADAs for Diarrhea in Companion Animals and Horses
March 03, 2014 03:15 PM Eastern Standard Time SAN FRANCISCO--( BUSINESS WIRE )--Jaguar Animal Health, Inc. (“Jaguar”) announced today that it has submitted three Investigational New Animal Drug Applications (“INADA”) with the Center for Veterinary Medicine of the US Food and Drug Administration
Toggle Summary Jaguar Announces Initial Close of Series A Round
SAN FRANCISCO , Feb. 5, 2014 /PRNewswire/ -- Jaguar Animal Health, Inc. ("Jaguar") announced an initial $2 million closing of its Series A round of financing.   BioVeda China Fund ("BVCF"), a private equity and growth capital investor based in China, funded the initial closing and
Toggle Summary Drug Application For Chemo-induced Diarrhea In Dogs Moving Forward
SAN FRANCISCO Jan. 14, 2014 /PRNewswire/ -- An investigational new animal drug application (INADA) number has been received by Napo Pharmaceuticals, Inc. for its lead animal drug candidate, SP-303, which is isolated and purified from Croton lechleri, a medicinal plant sustainably harvested from the